YS Biopharma Past Earnings Performance
Past criteria checks 0/6
YS Biopharma's earnings have been declining at an average annual rate of -34.7%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 19% per year.
Key information
-34.7%
Earnings growth rate
-0.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 19.0% |
| Return on equity | -76.6% |
| Net Margin | -61.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How YS Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 544 | -334 | 427 | 342 |
| 30 Sep 23 | 561 | -309 | 373 | 374 |
| 30 Jun 23 | 658 | -195 | 363 | 349 |
| 31 Mar 23 | 687 | -145 | 348 | 319 |
| 31 Dec 22 | 698 | -95 | 370 | 265 |
| 30 Sep 22 | 633 | -72 | 350 | 211 |
| 30 Jun 22 | 574 | -103 | 317 | 219 |
| 31 Mar 22 | 503 | -106 | 288 | 211 |
| 31 Mar 21 | 257 | -192 | 225 | 94 |
Quality Earnings: YS is currently unprofitable.
Growing Profit Margin: YS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if YS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare YS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: YS has a negative Return on Equity (-76.55%), as it is currently unprofitable.